In this sense, pre-clinical studies have shown selective effects of anti-CCR7 mAbs for CLL cells while sparing healthy counterparts, even at saturating concentrations of antibody (52, 63, 223, 224). This evidence concerns the gene CCR7 and B-cell chronic lymphocytic leukemia.